id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-4159	Borghi, Alessandro; Odorici, Giulia; Bardazzi, Federico; Filippi, Federica; Bigi, Laura; Lasagni, Claudia; Manfredini, Marco; Di Lernia, Vito; Peccerillo, Francesca; Conti, Andrea; Tiberio, Rossana; Satolli, Francesca; Fantini, Carolina; Rovesti, Miriam; Gasperini, Massimo; Tabanelli, Michela; D'Adamio, Simone; Flacco, Maria Elena; Corazza, Monica	Real-Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience	2024	4	.pdf	application/pdf	1852	91	53	Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, gusel- kumab, risankizumab, tildrakizumab for psoriasis treatment. Mean PASI % reduction between baseline and week 12, (SD) 77.8 (25.9) 82.2 (18.7) 89.8 (20.5) 67.4 (31.4) b, c Baseline-week 12 PASI reduction ≥75%, % 63.3 67.3 86.1 48.8 a, b, c Baseline-week 12 PASI reduction ≥90%, % 45.0 45.8 72.2 32.6 a, c Baseline-week 12 PASI 100% decrease, % 34.1 30.8 69.4 23.3 a, b, c Mean PASI at week 16 (SD) 1.8 (3.0) 1.6 (2.4) 1.2 (2.5) 4.4 (5.1) b, c Mean PASI % reduction between baseline and week 16, (SD) 81.9 (39.5) 82.6 (41.3) 86.6 (30.4) 64.5 (51.0) Baseline-week 16 PASI 90% decrease, % 64.7 64.9 75.0 33.3 b, c Baseline-week 16 PASI 100% decrease, % 47.4 39.2 68.2 26.7 a, c Mean PASI at week 28 (SD) 1.5 (3.3) 1.2 (2.9) 1.5 (2.8) 1.9 (4.0)	cache/dpc-4159.pdf	txt/dpc-4159.txt